Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Glucose Control and Cardiovascular Disease – 15 Year Follow-up
Dapagliflozin vs. Saxagliptin: Durability of Glycemic Control
Risk Factors for Advanced Kidney Disease in Patients with Type 1 Diabetes
MOST POPULAR ARTICLES OF THE MONTH
#1 Updated Consensus Report on Diabetic Nutrition Therapy
Editor's Note
The FDA gave approval to Tandem’s Control IQ this past week and the word is on the streets already. My wife was at the endo office today and he was telling her about it, and told her it would improve her 6.1 A1c. He also mentioned that he may have to move from his Medtronic to the Dexcom/Tandem combination.
LILLY jumped back in the diabetes management arena as today they announced a collaboration with Dexcom to deliver information to the phone to be used with their new disposable pens that communicate. Interestingly enough they also announced that they were going to develop an insulin pump as well. Hmmm, have I heard that before?
Dave Joffe
Editor-in-chief
Newsflash: Lilly to Integrate Dexcom CGM into Personalized Diabetes Management System
Lilly and Dexcom reached an agreement to integrate Dexcom’s sensor into Lilly’s insulin delivery systems, which include connected insulin pens that will be disposable and will communicate with a smartphone and yes, an insulin pump.
TOP STORIES — Diabetes News and Research
Does intensive glucose control show heart benefits in long-term followup?.
The persistence of benefits of dapagliflozin over saxagliptin might change therapy choices in patients with type 2 diabetes.
How to identify who is at risk for the progression of diabetic kidney disease to end-stage renal disease?
About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.